A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung ...
Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.
A major contributor to obesity-related pathology is inflammation involving a shift in macrophage polarization toward the inflammatory M1 phenotype and accumulation of such macrophages in the liver and ...
The myeloid differentiation primary response 88 (MYD88) gene L256P mutation appears to be frequent among patients with chronic inflammatory demyelinating polyneuropathy (CIDP), the finding could have ...
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, ...
Cell lines have enabled a comprehensive understanding of disease biology and the advancement of new therapeutics in Waldenström macroglobulinaemia (WM). Herein, we report the development of BCWM.2, a ...
Researchers from Wenzhou Medical University and affiliated organizations presented the discovery and preclinical characterization of novel myeloid differentiation primary response 88 (MyD88) inhibitor ...
NEW YORK — In the wake of details about the molecular pathophysiology of Waldenström macroglobulinemia (WM), an expert gave an update on current and expanding options for treatment. Most importantly, ...
It is rare for patients with chronic lymphocytic leukemia (CLL) to present with ocular involvement, but a mutational test could help clinicians identify patients more quickly. Testing for myeloid ...
Kymera Therapeutics has been granted a patent for a method to treat MYD88-mutant B-cell lymphomas using an IRAK4 degrader. The method involves administering Compound A or its salt to the patient at a ...
A hand holding white capsules Zanubrutinib is as effective as — but safer than — ibrutinib for patients with Waldenström macroglobulinemia, a phase 3 trial suggests. Zanubrutinib is as effective as — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results